Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients 24 and treatment options are limited by toxicities. CSJ148 is a combination of two anti-HCMV 25 human monoclonal antibodies (LJP538 and LJP539) that bind to and inhibit the function of viral 26 HCMV glycoprotein B (gB) and the pentameric complex, consisting of glycoproteins gH, gL, 27 UL128, UL130, and UL131. In this Phase 2 randomized placebo-controlled trial, we evaluated 28 the safety and efficacy of CSJ148 for prophylaxis of HCMV in patients undergoing allogeneic 29 hematopoietic stem cell transplant. As would be expected in the study population, all patients 30 (100%) reported at least one treatment-emergent adverse event. There were 22 deaths during this 31 study and over 80% of patients receiving placebo or CSJ148 developed at least one adverse 32 event of Grade 3 or higher severity. No subject who received antibody developed a 33 hypersensitivity or infusion-related reaction. CSJ148-treated patients showed trends toward 34 decreased viral load, shorter median duration of preemptive therapy, and fewer courses of 35 preemptive therapy. However, the estimated probability that CSJ148 decreases the need for 36 preemptive therapy compared to placebo was 69%, with a risk ratio of 0.89 and 90% credible 37 interval of 0.61 to 1.31. The primary efficacy endpoint was therefore not met, indicating that 38 CSJ148 did not prevent clinically significant HCMV reactivation in recipients of allogeneic 39 hematopoietic cell transplant. (ClinicalTrials.gov Identifier NCT02268526; EudraCT Number 40 2017-002047-15.) 41 42 on February 26, 2020 by guest http://aac.asm.org/ Downloaded from 43
INTRODUCTION
The posterior distribution for pT / pC (the risk ratio) was computed and summarized in a similar fashion. Additionally, posterior probabilities (confidence levels) that the risk ratio is <1 152 and <0.5 were computed. Table 1) , five completed the study. In Cohort 2, 80 patients were enrolled and 54 169 patients (38 in the CSJ148 group and 16 in the placebo group) completed the study. The most 170 common reasons for discontinuations were death (12; 14.0%), subject decision (10; 11.6%), and 171 adverse event (3; 3.5%). The most common reasons for exclusion from the PD analysis sets were use of medication with anti-HCMV activity prior to meeting a primary endpoint, withdrawal 173 from the study or death prior to meeting the primary endpoint or Day 99 (whichever came first), 174 and missing a study drug dose prior to meeting the primary endpoint (Supplemental Methods). 175 Baseline demographics and other characteristics were generally comparable between 176 CSJ148 and placebo-treated patients ( Table 2) . All patients were HCMV seropositive before 177 transplantation. However, the median age of CSJ148 patients (56 years) was older than that of 178 the placebo-treated patients (44 years). In addition, CSJ148-treated patients were predominantly 179 white, while the placebo-treated patients were predominantly Asian. Based on differences of at 180 least 10%, potentially relevant differences in baseline transplant characteristics included more 181 CSJ148-treated patients receiving a graft from unrelated donors, from HCMV seronegative 182 donors, and a marrow graft, while more placebo-treated patients received T cell depleted grafts, 183 and peripheral blood stem cells. The majority of patients received a graft from a complete match 184 donor (80% and 71.4% in CSJ148 and placebo-treated patients, respectively); haploidentical 185 donors were used in 23.8% of CSJ148 and 15.4% of placebo-treated patients. Table 3) .
The median viral load at the initiation of preemptive therapy for CSJ148-treated patients was 1,914 copies/mL (range 120 to 45,430 copies/mL) compared with 5,555 196 copies/mL (range 875 to 15,620 copies/mL) for placebo-treated patients. One subject who 197 received CSJ148 had HCMV viral loads below the limit of quantification. For patients who 198 had HCMV viral load > 1000 copies/mL at the initiation of the first course of preemptive 199 therapy (n=29), 13/20 (65%) CSJ148-treated patients and 6/9 (67%) placebo-treated patients 200 achieved viral load below the lower limit of quantification before the end of treatment on Day 99.
201
The median time to achieve a viral load below the lower limit of quantification after the 202 first course of preemptive therapy was shorter in CSJ148-treated (median 20 days; range 5-203 36 days) compared with placebo-treated patients (median 30 days; range 15-52 days). The 204 median time to start of therapy was 97.6 days (95% CI: 76.5, not calculated) and 80.6 days (95% period, two CSJ148-treated and one placebo-treated patients developed HCMV disease; none 218 had prior GVHD.
219
Exploratory post-hoc analyses using the combined PD analysis set were performed to 220 determine if the lack of efficacy could be explained in part by confounding factors. Although this 221 is a post-hoc assessment and the sample size is too small to draw definitive conclusions, 222 potentially relevant associations of three baseline factors and one post-enrollment factor with the 223 primary outcome were noted (based on Cochran Mantel Hazard test p-value ≤0.300, Table 4 ). 224 The baseline factors were receiving a myeloablative versus a non-myeloablative conditioning 
231
Three of the four potentially confounding factors showed a trend for association with 232 treatment group. Proportionally more CSJ148-treated patients received a transplant from an 233 unrelated donor (p=0.254) and developed acute GVHD (p=0.160). Proportionally more patients 234 who received placebo received myeloablative conditioning regimen (p=0.272) ( Table 5) .
The most common (>50% incidence) treatment-emergent adverse events were nausea 261 (70% of total patients), diarrhea (65%), vomiting (61%), stomatitis (59%) and pyrexia 262 (57%). The incidence of Grade 3 or higher adverse events was similar among CSJ148-and 263 placebo-treated patients. Based on an absolute difference of at least 10%, however, eight 264 adverse events occurred more frequently in CSJ148-treated patients (diarrhea, hypertension, 265 dizziness, hemorrhoids, arthralgia, and non-cardiac chest pain) and three occurred more 266 frequently in placebo-treated patients (stomatitis, upper abdominal pain, and neutropenia).
267
Only two adverse events were assessed as possibly related to study drug (fever and 268 thrombocytopenia); both occurred in patients receiving placebo. The adverse events occurring in 269 more than 10% of either treatment group are listed in Table S1 . 270 Fifty-eight of sixty-five (89.2%) CSJ148-treated and 17/21 (81.0%) of placebo-treated 271 patients had at least one Grade 3 or higher adverse event; the most common were febrile 272 neutropenia (30.2% of total patients), stomatitis (18.6%), and hypertension (15.1%) ( Table 6) . 273 In general, the incidence of all adverse events was similar for CSJ148-and placebo-treated 274 patients. Based on an absolute difference of at least 10%, stomatitis and acute graft versus host 275 disease occurred more frequently in CSJ148-treated patients and no adverse event occurred 276 more frequently in placebo-treated patients. As expected in the population studied, all patients 277 experienced hematologic abnormalities. Among Grade 4 hematologic adverse events with 278 differences of at least 10%, patients in the CSJ148 group had more frequent decreased platelet 279 counts (73.8% versus 61.9% in placebo) and decreased neutrophil count (53.8% versus 33.3% in 280 placebo), while Grade 4 reduction in lymphocyte count was more common in placebo-treated 281 patients (100%) compared with CSJ148-treated patients (84.6%) ( Table S2 ). Most clinical chemistry abnormalities were assessed as being part of the underlying disease process and transplant, related to a subsequent adverse event, or considered not clinically relevant. during follow up (day 100 to 183), and seven (10.8%) after the end-of-study visit (after day 297 184). All deaths in placebo-treated patients occurred after the end-of-treatment visit; with two 298 (9.5%) deaths during the follow-up period and one (4.8%) after the end-of-study visit. No 299 patient deaths were suspected to be related to study drug, and all causes of death were 300 consistent with those expected after allogeneic HCT (Table S3 ).
acute GVHD compared with those who received placebo (29%), and the development of acute 352 GVHD was associated with a greater risk of requiring preemptive therapy for HCMV (71% 353 versus 26% if acute GVHD did not occur) in CSJ148-treated patients. CSJ148-treated patients 354 (55%) were more likely to have received a graft from an unrelated donor compared with those 355 who received placebo (33%), and unrelated grafts appeared to be also associated with a greater Together these data suggest that the failure to meet the primary endpoint could be due to an 373 inability of CSJ148 to overcome the severe deficiencies in T cell immunity seen among HCT patients in this study. However, CSJ148 did appear to have anti-HCMV activity and CSJ148 (6.2% and 28.6%, respectively), and a higher proportion of non-related transplants (55.4% 398 and 33.3%, respectively); both are risk factors for GVHD (25, 27). Pooled immunoglobulin 399 and monoclonal antibody preparations are not known to cause or promote GVHD.
400
Overall mortality in the study population was consistent with the reported mortality in 401 HCT patients (29% to 66%) (28). All causes of death were consistent with those expected after 402 HCT, and none were suspected to be related to study drug by the investigators. A plausible, 403 direct, causal relationship between CSJ148 treatment and increased mortality was not 404 identified, and the majority of deaths occurred after the treatment period (during follow-up or 405 after study completion). Although the sample size is too small to draw definitive conclusions, 406 post-hoc analysis identified older age as a potential confounder for mortality. Other factors 407 potentially associated with mortality examined included age (>40 versus ≤40 years of age), 408 donor type (unrelated versus related), and presence of acute GVHD. Although none of these 409 showed a trend for a potentially relevant association, all have been reported to increase the 410 risk of death by others (28, 29). Taken together, the data suggest a relatively higher mortality 411 rate among CSJ148-treated patients compared to placebo-treated patients being driven by these 412 patients having a higher mortality risk at baseline.
413
In conclusion, consistent with the experience in healthy volunteers, CSJ148 was well 414 tolerated and appears to have anti-HCMV activity. However, treatment did not prevent 415 clinically significant HCMV reactivation in HCMV seropositive allogeneic HCT recipients. 
